8-K: Tyra Biosciences Receives FDA Clearance for Phase 2 Trial of TYRA-300 in Children with Achondroplasia

Tyra Biosciences has announced that the FDA has cleared its Investigational New Drug application for TYRA-300, allowing the company to proceed with a Phase 2 clinical trial for children with achondroplasia.

Summary

• Tyra Biosciences has received FDA clearance to begin a Phase 2 clinical trial (BEACH301) for TYRA-300 in children with achondroplasia.
• The BEACH301 study is a multicenter, open-label, dose-escalation/dose-expansion study that will evaluate TYRA-300 in children aged 3 to 10 with achondroplasia and open growth plates.
• The study will include both treatment-naive children (Cohort 1) and those who have previously received growth-accelerating therapy (Cohort 2), with each cohort expected to enroll up to 10 participants per dose level.
• A safety sentinel cohort of up to 3 treatment-naive participants per dose level in children ages 5 to 10 will be enrolled prior to Cohorts 1 and 2.
• The primary objectives of the study are to assess safety and tolerability and to determine the dose(s) for further development by evaluating changes in annualized growth velocity.
• Secondary objectives include evaluating changes in height z-score, proportionality, and pharmacokinetics.
• The company also plans to conduct exploratory assessments of clinical outcomes such as functional improvements, changes in the spine, and quality of life measures.
• Tyra Biosciences expects to dose the first child in the BEACH301 study in the first quarter of 2025.
• The company also plans to submit an IND for a Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer (NMIBC) by the end of 2024.

Sentiment

Score: 7

Explanation: The document is positive due to the FDA clearance and advancement of the clinical program, but tempered by the inherent risks and uncertainties of drug development.

Positives

• FDA clearance of the IND application for TYRA-300 is a significant milestone for the company.
• The Phase 2 BEACH301 study will evaluate TYRA-300 in a pediatric population with a high unmet medical need.
• The study design includes multiple dose levels and cohorts, allowing for a comprehensive evaluation of the drug.
• The inclusion of exploratory assessments of clinical outcomes provides a broader understanding of the drug's potential benefits.
• The planned IND submission for NMIBC expands the potential applications of TYRA-300.

Negatives

• The company is early in its development efforts and has only recently begun testing TYRA-300 and TYRA-200 in clinical trials.
• The approach the company is taking to discover and develop drugs based on the company's SNP platform is novel and unproven.
• There is a risk of potential delays in the commencement, enrollment, data readouts, and completion of preclinical studies and clinical trials.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• Interim results of a clinical trial are not necessarily indicative of final results.

Risks

• Later developments with the FDA may be inconsistent with prior feedback.
• The company's novel SNP platform may not lead to successful product candidates.
• There are potential delays in clinical trial commencement, enrollment, and data readouts.
• Preclinical and early clinical trial results may not predict future outcomes.
• Interim clinical trial results may not be indicative of final results.
• There is a risk that proof-of-concept results may not lead to successful development of TYRA-300.
• The company depends on third parties for manufacturing, research, and preclinical testing.
• The FDA may not accept INDs or similar regulatory submissions.
• An accelerated development or approval pathway may not be available.
• Unexpected adverse side effects or inadequate efficacy may limit development.
• The company's programs may be negatively impacted by competitors.
• The company may not realize the benefits of Orphan Drug Designation or Rare Pediatric Disease Designation.
• Regulatory developments in the US and foreign countries could impact the company.
• The company's ability to obtain and maintain intellectual property protection is a risk.

Future Outlook

Tyra Biosciences plans to initiate the BEACH301 study in the first quarter of 2025 and submit an IND for a Phase 2 study of TYRA-300 in NMIBC by the end of 2024. The company is also focused on the potential safety and therapeutic benefits of TYRA-300.

Industry Context

The announcement is significant in the context of rare disease drug development, particularly for achondroplasia, where there is a high unmet medical need. The company's focus on a novel SNP platform also positions it as an innovator in the field.

Comparison to Industry Standards

• The Phase 2 trial design for TYRA-300 is consistent with industry standards for early-stage clinical trials in rare diseases, including dose escalation and safety sentinel cohorts.
• Other companies developing therapies for achondroplasia include BioMarin with Voxzogo, which is already approved, and Ascendis Pharma with TransCon CNP, which is in clinical development. Tyra's approach with TYRA-300 is different, targeting a specific genetic pathway.
• The planned Phase 2 study in NMIBC is also in line with industry trends, as there is a growing focus on developing new therapies for bladder cancer.

Stakeholder Impact

• Shareholders will likely view the FDA clearance and clinical trial initiation positively.
• Patients and families affected by achondroplasia may see this as a promising development.
• Employees of Tyra Biosciences will be involved in the execution of the clinical trials.
• The company's suppliers and research partners will be involved in the clinical trial process.

Next Steps

• Initiate the BEACH301 study in the first quarter of 2025.
• Submit an IND for a Phase 2 study of TYRA-300 in NMIBC by the end of 2024.

Key Dates

Keywords

TYRA-300, Achondroplasia, Clinical Trial, FDA, Investigational New Drug, BEACH301, NMIBC, Phase 2, Pediatric, Growth Velocity